{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:08:35Z","timestamp":1777468115560,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009709","name":"Stichting De Weijerhorst","doi-asserted-by":"publisher","award":["PC-00128-5"],"award-info":[{"award-number":["PC-00128-5"]}],"id":[{"id":"10.13039\/501100009709","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Guidelines on safe use of iodinated contrast material recommend intravenous prophylactic hydration to prevent post-contrast adverse (renal) effects. Recently, guidelines have been updated and standard prophylaxis is no longer recommended for the majority of patients. The current study aims to evaluate the consequences for clinical practice of the updated guidelines in terms of complications, hospitalisations, and costs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The Contrast-Induced Nephropathy After Reduction of the prophylaxis Threshold (CINART) project is a retrospective observational study. All elective procedures with intravascular iodinated contrast administration at Maastricht University Medical Centre (UMC+) in patients aged &gt;\u200918\u00a0years, formerly eligible for prophylaxis (eGFR 30\u201344\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> or eGFR 45\u201359\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> in combination with diabetes or &gt;\u20091 predefined risk factor), and currently eligible for prophylaxis (eGFR &lt;\u200930\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>) were included. Data were used to calculate relative reductions in complications, hospitalisations, and costs associated with standard prophylactic intravenous hydration. CINART is registered with <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>: NCT03227835.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Between July 1, 2017, and July 1, 2018, 1992 elective procedures with intravascular iodinated contrast in patients formerly and currently eligible for prophylaxis were identified: 1808 in patients formerly eligible for prophylaxis and 184 in patients currently eligible for prophylaxis. At Maastricht UMC+, guideline updates led to large relative reductions in numbers of complications of prophylaxis (e.g. symptomatic heart failure; \u2212\u200989%), extra hospitalisations (\u2212\u200993%), and costs (\u2212\u200991%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Guideline updates have had a demonstrable impact on daily clinical practice benefiting patient, hospital, and health care budgets. Clinical practice varies between institutions and countries; therefore, a local estimation model is provided with which local impact on costs, hospitalisations, and complications can be calculated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Key Points<\/jats:title>\n<jats:p><jats:italic>\u2022 Clinical practice guidelines recommend prophylactic intravenous hydration to prevent post-contrast adverse outcomes such as contrast-induced acute kidney injury.<\/jats:italic><\/jats:p>\n<jats:p><jats:italic>\u2022 Clinical practice guidelines have recently been updated, and standard prophylaxis is no longer recommended for the majority of patients.<\/jats:italic><\/jats:p>\n<jats:p><jats:italic>\u2022 The guideline updates have a large impact on daily clinical practice: relative reductions at Maastricht UMC+ were \u2212\u200989% prophylaxis complications, \u2212\u200993% hospitalisations, and \u2212\u200991% costs, and similar reductions are expected for Dutch and adherent European medical centres.<\/jats:italic><\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00330-020-06719-7","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T15:03:03Z","timestamp":1582815783000},"page":"4005-4013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact on clinical practice of updated guidelines on iodinated contrast material: CINART"],"prefix":"10.1007","volume":"30","author":[{"given":"E. C.","family":"Nijssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Nelemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Rennenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. V.","family":"van Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Wildberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"6719_CR1","unstructured":"European Society of Urogenital Radiology. ESUR guidelines on contrast media. Available via: http:\/\/www.esur.org\/guidelines\/ (old version) & http:\/\/www.esur.org\/esur-guidelines\/ (newest versions). Accessed 24 Jan 2020"},{"key":"6719_CR2","unstructured":"Nederlandse Vereniging voor Radiologie. Guideline Safe Use of Contrast Media. Available via: https:\/\/www.radiologen.nl\/kwaliteit\/richtlijnen-veilig-gebruik-van-contrastmiddelen-guidelines-safe-use-contrast-media. Accessed 24 Jan 2020"},{"key":"6719_CR3","unstructured":"Committee on Drugs and Contrast Media, American College of Radiology (ACR). Manual on contrast media. Available via: http:\/\/www.acr.org\/quality-safety\/resources\/contrast-manual. Accessed 24 Jan 2020"},{"key":"6719_CR4","unstructured":"Canadian Association of Radiologists. Consensus guidelines for the prevention of contrast induced nephropathy. Available via: https:\/\/car.ca\/wp-content\/uploads\/Prevention-of-Contrast-Induced-Nephropathy-2011.pdf. Accessed 24 Jan 2020"},{"key":"6719_CR5","unstructured":"The Royal Australian and New Zealand College of Radiologists. RANZCR iodinated contrast guidelines. Available via: https:\/\/www.ranzcr.com\/college\/document-library\/ranzcr-iodinated-contrast-guidelines. Accessed 24 Jan 2020"},{"key":"6719_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(17)30057-0","volume":"389","author":"EC Nijssen","year":"2017","unstructured":"Nijssen EC, Rennenberg RJ, Nelemans PJ et al (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high-risk of contrast-induced acute kidney injury (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 389:1312\u20131322","journal-title":"Lancet"},{"key":"6719_CR7","doi-asserted-by":"crossref","unstructured":"Nijssen EC, Nelemans PJ, Rennenberg RJ, van Ommen GV, Wildberger JE (2018) Prophylactic intravenous hydration to protect renal function from intravascular iodinated contrast material (AMACING): long-term results of a prospective, randomised, controlled trial. EClinicalMedicine 4\u20135:109\u2013116","DOI":"10.1016\/j.eclinm.2018.10.007"},{"key":"6719_CR8","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","volume":"28","author":"AJ Van der Molen","year":"2018","unstructured":"Van der Molen AJ, Reimer P, Dekkers IA et al (2018) Post-contrast acute kidney injury- part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28:2845\u20132855","journal-title":"Eur Radiol"},{"key":"6719_CR9","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","volume":"28","author":"AJ Van der Molen","year":"2018","unstructured":"Van der Molen AJ, Reimer P, Dekkers IA et al (2018) Post-contrast acute kidney injury. Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients. Eur Radiol 28:2856\u20132869","journal-title":"Eur Radiol"},{"key":"6719_CR10","unstructured":"The National Institute for Health and Care Excellence (2017) Surveillance report (exceptional review) 2017 \u2013 Acute kidney injury: prevention, detection and management 2013 NICE guideline CG169. Available via: https:\/\/www.nice.org.uk\/guidance\/ng148\/evidence\/a-preventing-contrastinduced-acute-kidney-injury-pdf-7019265566. Accessed 24 Jan 2020"},{"key":"6719_CR11","unstructured":"Veligheids Management Systeem (2009) VMS veiligheidsprogramma: voorkomen van nierinsuffici\u00ebntie bij intravasculair gebruik van jodiumhoudende contrastmiddelen. Available via: http:\/\/www.vmszorg.nl\/themas\/nierinsufficientie. Accessed 24 Jan 2020"},{"key":"6719_CR12","unstructured":"Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold (CINART). Clinicaltrials.gov. Available via: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03227835. Accessed 24 Jan 2020"},{"key":"6719_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/RLI.0000000000000570","volume":"54","author":"EC Nijssen","year":"2019","unstructured":"Nijssen EC, Nelemans PJ, Rennenberg RJ, Theunissen RAT, van Ommen GV, Wildberger JE (2019) Prophylaxis in high-risk patients with eGFR <30 ml\/min\/1.73m2: get the balance right. Invest Radiol 54:580\u2013588","journal-title":"Invest Radiol"},{"key":"6719_CR14","unstructured":"Burgess WP, Walker PJ (2014) Mechanisms of contrast-induced nephropathy reduction for saline (NaCl) and sodium bicarbonate (NaHCO3). Biomed Res Int 2014:510385"},{"key":"6719_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/RLI.0000000000000479","volume":"53","author":"EC Nijssen","year":"2018","unstructured":"Nijssen EC, Nelemans PJ, Rennenberg RJ, van Ommen GV, Wildberger JE (2018) Evaluation of safety guidelines on the use of iodinated contrast material: conundrum continued. Invest Radiol 53:616\u2013622","journal-title":"Invest Radiol"},{"key":"6719_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.crad.2017.07.002","volume":"72","author":"LH Cope","year":"2017","unstructured":"Cope LH, Drinkwater K, Howlett DC (2017) RCR audit of compliance with UK guidelines for the prevention and detection of acute kidney injury in adult patients undergoing iodinated contrast media injections for CT. Clin Radiol 72:1047\u20131052","journal-title":"Clin Radiol"},{"key":"6719_CR17","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/S0140-6736(14)60689-9","volume":"383","author":"SS Brar","year":"2014","unstructured":"Brar SS, Aharonian V, Mansukhani P et al (2014) Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 383:1814\u20131823","journal-title":"Lancet"},{"key":"6719_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.tox.2004.12.020","volume":"209","author":"C Christiansen","year":"2005","unstructured":"Christiansen C (2005) X-ray contrast media: an overview. Toxicology 209:185\u2013187","journal-title":"Toxicology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-020-06719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-020-06719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-020-06719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:22:03Z","timestamp":1614298923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-020-06719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["6719"],"URL":"https:\/\/doi.org\/10.1007\/s00330-020-06719-7","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is JE Wildberger.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Dr. Wildberger declares the following institutional grants to the Department of Radiology and Nuclear Medicine, Maastricht UMC+ (via Clinical Trial Center Maastricht): Agfa Healthcare, Bayer Healthcare, General Electric, Optimed, Philips Healthcare, Siemens Healthcare. Speakers bureau (JEW\/ Clincial Trial Center Maastricht): Bayer, Siemens. These grants and fees are not related to the contents of this manuscript.The other authors declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by The Medical Research Ethics Committee Maastricht UMC+.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}